Three-year deal under which PDI will provide marketing services for three oncology products from Align
PDI initially will provide a sales team of 40 representatives; the products are Numoi- syn Lozenges and Numoisyn Liquid, for dry mouth, and Xclair, for radiation dermatitis (1/19)
Bumimedic Sdn. Bhd. (Malaysia; part of the Antah HealthCare Group)
Bumimedic will market ABI's low-dose interferon product in Malaysia
ABI is entitled to a series of payments through approval and production, and would get royalties on sales (1/19)
Techcomp Holdings Ltd. (China)
Techcomp will distribute Ciphergen's ProteinChip products in China, Singapore, Malaysia, Vietnam and Indonesia
They also entered a product development and manufacturing deal for sample preparation technology and an associated device; Ciphergen would sell resulting products (1/17)
Laureate Pharma Inc.
Discovery is purchasing Laureate's manufacturing operations in Totowa, N.J.
Laureate has been providing manufacturing services to Discovery for more than two years; Discovery is paying $16M in cash for the facility (12/28)
Stiefel Laboratories Inc.
Stiefel got rights to distribute DUSA's Levulan Kerastick for photodynamic therapy in dermatology in Latin America
The deal has an initial terms of 10 years; Stiefel will take over regulatory responsibilities; terms were not disclosed (1/18)
Cambrex Bio Science Walkersville Inc.
Deal for the manufacture of Geron's GRNVAC1 telomerase vaccine
The vaccine is comprised of autologous dendritic cells loaded ex vivo with telomerase mRNA; terms of the deal were not disclosed (2/13)
MDS Nordion (Canada)
Six-year deal under which MDS will manufacture and supply Zemiva for MIPI
The molecular imaging agent is being developed for cardiac ischemia; terms of the deal were not disclosed (2/16)
Nigaard Pharma A/S (Norway)
Nigaard got marketing rights to Aridol in the Scandinavian countries
Aridol is an asthma management tool; terms of the deal were not disclosed (1/18)
The unnamed company will promote TopoTarget's Savene in Austria and four Eastern European countries
The drug is being developed for treating accidental extravasations of anthracycline drugs; launch is anticipated late in 2006 (12/22)
Viventia licensed rights to use Dow's Pfenex Expression Technology in antibody production
Viventia will use the technology in up to six compounds; Dow is entitled to milestone and royalty payments in the deal (2/14)
# The information in the chart does not cover agricultural agreements or those between biotech companies.
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
CSE = Copenhagen Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.